RenovoRx, Inc.

MOUNTAIN VIEW, CA · Founded 2012 · Medtech · Public

RenovoCath™, a dual-balloon infusion catheter for targeted chemotherapy delivery to pancreatic tumors

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · renovorx.com

Sector: Medtech
Headquarters: MOUNTAIN VIEW, CA
Founded: 2012
Latest Form D: $10M, Apr 2026
Total capital: $39.5M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $39.5M; 7 Form D · last Apr 2026; 7 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 8; 17 pending · first 2016; Rank in peer group#229 of 1112

Capital timeline

Latest events

Apr 2026Private capital raisedForm D · SEC · 7th filing$10M
Apr 2024Private capital raisedForm D · SEC · 6th filing$11.1M
Feb 2024Private capital raisedForm D · SEC · 5th filing$6.1M
Jun 2018Private capital raisedForm D · SEC · 4th filing$8.3M
Jan 2016Private capital raisedForm D · SEC · 3rd filing$2.1M
Dec 2013Private capital raisedForm D · SEC · 2nd filing$1.1M
Apr 2013Private capital raisedForm D · SEC · 1st filing$660K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1112 peers

Line = median

Medtech · Device

Granted patents#229 · top 21%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Ramtin R. AgahResearcherExecutive OfficerLinked by 8 patents
Angela Gill NelmsExecutive OfficerNamed in SEC Form D filings
Frank J. RahmaniExecutive OfficerNamed in SEC Form D filings
Joost J. de SchutterExecutive OfficerNamed in SEC Form D filings
Kamran R. NajmabadiExecutive OfficerNamed in SEC Form D filings
Kirsten Angela MacfarlaneDirectorNamed in SEC Form D filings

Show all 21 people

Klaus W. HambuechenDirectorNamed in SEC Form D filings
Laurence J. MartonDirectorNamed in SEC Form D filings
Laurence J. Marton, M.D.DirectorNamed in SEC Form D filings
Leesa R. GentryExecutive OfficerNamed in SEC Form D filings
Mark R. VollExecutive OfficerNamed in SEC Form D filings
Marta Gaia Zanchi, PhDExecutive Officer, DirectorNamed in SEC Form D filings
Marta Gaia Zanchi, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
Ramtin Gaia Agah, M.D.DirectorNamed in SEC Form D filings
Robert J. SpiegelDirectorNamed in SEC Form D filings
Ronald B. KocakExecutive OfficerNamed in SEC Form D filings
Ron R. KocakExecutive OfficerNamed in SEC Form D filings
Shaun R. BagaiExecutive Officer, DirectorNamed in SEC Form D filings
Una S. RyanDirectorNamed in SEC Form D filings
Una S, Ryan, PhDDirectorNamed in SEC Form D filings
Una S. Ryan, Ph.D.DirectorNamed in SEC Form D filings

What it has protected

USPTO · 8 granted of 25

Oct 30, 2025PendingMethods For Treating TumorsUSPTOApplication 19195733
May 6, 2025GrantedMethods And Apparatuses For Treating TumorsUSPTOUS 12,290,564
Nov 9, 2023PendingMethods For Delivery Of Therapeutic Materials To Treat CancerUSPTOApplication 18149649

Show all 25 patent records

Methods For Treating TumorsOct 30, 2025 · Application 19195733Pending
Methods And Apparatuses For Treating TumorsMay 6, 2025 · US 12,290,564Granted
Methods For Delivery Of Therapeutic Materials To Treat CancerNov 9, 2023 · Application 18149649Pending
Dual Occlusion Catheter SystemSep 28, 2023 · Application 18184620Pending
Methods For Delivery Of Therapeutic Materials To Treat CancerJan 3, 2023 · US 11,541,211Granted
Methods For Treating Cancerous TumorsNov 4, 2021 · Application 17367046Pending
Methods For Treating Cancerous TumorsJul 6, 2021 · US 11,052,224Granted
Methods For Delivery Of Therapeutic Materials To Treat CancerJul 2, 2020 · Application 16685950Pending
Methods For Treating Cancerous TumorsJun 30, 2020 · US 10,695,543Granted
Methods For Delivery Of Therapeutic Materials To Treat Pancreatic CancerDec 24, 2019 · US 10,512,761Granted
Occlusion Catheter System And Methods Of UseOct 16, 2018 · US 10,099,040Granted
Devices, Methods And Kits For Delivery Of Therapeutic Materials To A PancreasOct 11, 2016 · US 9,463,304Granted
Devices, Methods And Kits For Delivery Of Therapeutic Materials To A Target ArteryOct 4, 2016 · US 9,457,171Granted
Angiographic Methods For Identification Of Feeder VesselsMar 24, 2016 · Application 14958415Pending
Methods For Treating Cancerous TumorsApplication 62507962Pending
Methods And Apparatuses For Delivering An Agent Through The Vasa VasorumApplication 19129277Pending
Methods And Apparatuses For Delivering An Agent Through The Vasa VasorumApplication PCTUS2023037221Pending
Methods And Apparatuses For Delivering An Agent Through Vasa Vasorum Of A VesselApplication PCTUS2025029651Pending
Methods And Apparatuses For Delivering An Agent Through The Vasa VasorumApplication 63512903Pending
Methods And Apparatuses For Delivering An Agent Through Vasa Vasorum Of A VeinApplication 63647986Pending
Adjustable Dual-occlusion CathetersApplication 63710007Pending
Methods And Apparatuses For Delivering An Agent Through The Vasa VasorumApplication 63424842Pending
Methods For Delivery Of Therapeutic Materials For The Treatment Of CancerApplication 63320211Pending
Adjustable Dual-occlusion CathetersApplication PCTUS2025051941Pending
Methods For Treating Cancerous TumorsApplication PCTUS2018033482Pending

Spirair, Inc.Similar federal contract value in Medtech · null in contracts
Opio Connect, Inc.Similar federal contract value in Medtech · null in contracts
UNYQ DESIGN, INC.Similar federal contract value in Medtech · null in contracts
Ur24Technology, Inc.Similar federal contract value in Medtech · null in contracts
Pinnacle Transplant Technologies, LLCSimilar federal contract value in Medtech · null in contracts
Sabi Inc.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.